Clinical Trial Results, Share Repurchase Transactions, Stock Price Updates, Appointments, and Investments - Research Report on

 Clinical Trial Results, Share Repurchase Transactions, Stock Price Updates,
 Appointments, and Investments - Research Report on AbbVie, Express Scripts,
                    Actavis, Bristol-Myers Squibb, and GSK

PR Newswire

NEW YORK, December 13, 2013

NEW YORK, December 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting AbbVie
Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX), Actavis plc
(NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc
(ADR) (NYSE: GSK). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

AbbVie Inc. Research Report

On December 10, 2013, AbbVie Inc. (AbbVie) reported the release of Phase III
results for the investigational three direct-acting-antiviral (3D) regimen
plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus
(HCV) infection. According to AbbVie, in the 394-patient SAPPHIRE-II study,
96% of patients who previously failed pegylated interferon and ribavirin
treatment, including approximately 49% of those who were prior null
responders, achieved sustained virologic response at 12 weeks (SVR[12]) with
the regimen. Further, AbbVie said that the majority of patients were GT1a,
considered a difficult-to-treat subtype, and SVR12 rates of GT1a and GT1b were
96% and 97%, respectively. Lastly, AbbVie informed that virologic relapse or
breakthrough was observed in 2% of patients receiving the 3D regimen plus
ribavirin. Besides, the discontinuation rate due to adverse events was 1%.
"SAPPHIRE-II demonstrates that treatment-experienced genotype 1 HCV patients
achieved high rates of virologic response with AbbVie's interferon-free,
all-oral 3D regimen plus ribavirin," said Scott Brun, M.D., Vice President,
Pharmaceutical Development at AbbVie. The Full Research Report on AbbVie Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at: 

http://www.analystscorner.com/r/full_research_report/273c_ABBV

--

Express Scripts Holding Company Research Report

On December 10, 2013, Express Scripts Holding Company (Express Scripts)
announced that it has entered into an accelerated share repurchase (ASR)
transaction with Bank of America, N.A. to purchase shares of the Company's
common stock for an aggregate purchase price of $1.5 billion. Express Scripts
said that under the terms of the transaction, it will initially receive
approximately 20.1 million shares of its stock, and at the closure of the ASR
transaction, the Company will either be required to deliver shares of its
stock or the cash value thereof to Bank of America, or will receive additional
shares from Bank of America, depending upon the daily volume-weighted average
prices per share of the Company's stock during such valuation period. Express
Scripts informed that it expects the transaction to be completed by the end of
Q2 2014. The Full Research Report on Express Scripts Holding Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/91a7_ESRX

--

Actavis plc Research Report

On December 10, 2013, Actavis plc's (Actavis) stock declined 1.57%, ending the
day's session at $163.55. Over the previous three trading sessions, shares of
Actavis gained 0.40%, compared to the S&P 500 Index, which gained 0.99% during
the same period. The Full Research Report on Actavis plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/4997_ACT

--

Bristol-Myers Squibb Co. Research Report

On December 10, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb)
announced that the Company's Board of Directors has elected Thomas J. Lynch,
Jr., M.D., to its Board of Directors, effective from January 1, 2014. The
Company added that Dr. Lynch will serve as a member of the Science and
Technology Committee of the Board of Directors. James M. Cornelius, Chairman
of Bristol-Myers Squibb, said, "We are very pleased to have Tom join our
Board. His rare combination of skills and track record of success in both
medicine and business uniquely qualify him to serve on our Board of
Directors." According to the Company, Dr. Lynch currently serves as the
Director of the Yale Cancer Center and Physician-In-Chief of the Smilow Cancer
Hospital at Yale-New Haven. The Full Research Report on Bristol-Myers Squibb
Co. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

--

GlaxoSmithKline plc (ADR) Research Report 

On December 11, 2013, GlaxoSmithKline plc (ADR) (GSK) announced a series of
investments totaling c.£200 million in an effort to support the delivery of
the Company's pipeline of new medicines and create a center for pharmaceutical
manufacturing innovation in the UK. According to the Company, manufacturing
sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new
state-of-the art equipment, and a new facility will be established, dedicated
to harnessing innovative technologies with the potential to transform both the
way medicines are made and the Company's supply chain. GSK's investments
comprise: new manufacturing facilities in Ware for the Relvar^TM Ellipta^TM
inhaler; a new bulk sterile building and filling line for the Company's
antibiotic medicine Augmentin in Worthing; and a new centre for manufacturing
innovation, dedicated to transforming emerging science and technologies into
practical manufacturing applications, preferably located at Ware,
Hertfordshire. The Full Research Report on GlaxoSmithKline plc (ADR) -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2a35_GSK

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)